Chronic Hypertension
Chronic Hypertension - Related Videos
06:34
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
0 Views •
Cited by 26 •
2007
Glaucoma is one of the major causes of blindness in the world. Elevated intraocular pressure is a major risk factor. Laser photocoagulation induced ocular hypertension is one of the well established animal models. This video demonstrates how to induce ocular hypertension by Argon laser photocoagulation in rat.
09:22
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
0 Views •
Cited by 22 •
2015
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Right Ventricular (RV) dysfunction were induced in piglets by progressive obstruction of the pulmonary arteries. Consequences were remarkably similar to those observed in CTEPH patients. This animal model would be a very useful tool for pathophysiology and therapeutic experiments on CTEPH and RV failure.
07:00
A Laser-induced Mouse Model of Chronic Ocular Hypertension to Characterize Visual Defects
0 Views •
Cited by 26 •
2013
Chronic ocular hypertension is induced using laser photocoagulation of the trabecular meshwork in mouse eyes. The intraocular pressure (IOP) is elevated for several months after laser treatment. The decrease of visual acuity and contrast sensitivity of experimental animals are monitored using the optomotor test.
08:50
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
0 Views •
Cited by 30 •
2013
A two-stage method to establish chronic kidney disease (CKD) in the Lewis rat by surgically removing 5/6th of renal mass is described. Combination of the surgical procedure, NOS-inhibition and a high-salt diet leads to a model resembling human CKD, allowing study of causal mechanisms and development of novel therapeutic interventions.
09:40
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
0 Views •
Cited by 35 •
2016
Pulmonary arterial hypertension (PAH) is a disease of pulmonary arterioles that leads to their obliteration and the development of right ventricular failure. Rodent models of PAH are critical in understanding the pathophysiology of PAH. Here we demonstrate hemodynamic characterization, with right heart catheterization and echocardiography, in the mouse and rat.
FAQs
Increased vascular resistance makes it harder for blood to move through the circulation, so the heart must generate greater pressure to maintain blood flow. This raises afterload, the force opposing ventricular ejection, and increases the heart’s mechanical workload. Studying this relationship helps explain how vascular changes can influence both cardiovascular function and long-term disease risk.
Persistent changes in sodium and water regulation can increase fluid volume within the circulation, contributing to sustained elevation of arterial pressure. This mechanism connects kidney function with cardiovascular control rather than treating blood pressure as a purely vascular problem. It also explains why approaches that reduce fluid volume may help lower pressure and limit stress on organs.
Neurohormonal control links the nervous system and endocrine signaling with vascular tone and fluid balance. When these regulatory influences remain altered, they can support increased vascular resistance or retention of sodium and water, reinforcing elevated pressure over time. This systems-level perspective is important because chronic hypertension reflects interacting cardiovascular, renal, endocrine, and nervous processes.
Sustained arterial pressure exposes blood vessel walls to repeated mechanical stress and keeps the heart working against greater afterload. Over time, these pressures can contribute to injury involving the cardiovascular system, kidneys, and other organs. Risk assessment therefore considers more than the pressure value alone, since the duration and biological effects of elevation also matter.
Blood-pressure monitoring provides the measurements needed to identify persistent elevation and support ongoing risk assessment. Interpreting these measurements in biological context requires attention to the linked roles of vascular resistance, fluid regulation, and neurohormonal control. Monitoring is therefore useful both for evaluating the condition and for judging whether pressure-lowering strategies are addressing its underlying contributors.
The overview identifies two broad therapeutic targets: reducing vascular resistance and reducing fluid volume. Lowering resistance decreases the force opposing blood flow, while reducing volume addresses the contribution of sodium and water regulation. These approaches aim to lessen arterial pressure, reduce cardiac afterload, and limit the mechanical stress associated with cardiovascular, kidney, and other organ complications.